HSTM: Rounding Bottom detected on 14 May 2026

HealthStream reported Q1 2026 earnings on May 4 with a conference call on May 5, and the stock has formed a rounding bottom pattern near support at $19.47. Trading at $22.89, HSTM sits 17.57% above its 52-week low with a structure score of 10.0 and breakout score of 13.0—indicating a defined, gradual transition from downtrend to uptrend. Volume is inline at 1.02x average with solid technical confirmation. RSI at 56.49 shows neutral momentum without overbought extremes, while the measured move target of $23.88 represents modest upside. Overall score of 69.0 reflects a mid-quality setup with reasonable probability of breakout success.

HealthStream posted Q1 2026 revenues of $81.2 million, up 10.5% year-over-year, with operating income surging 71.6% to $7.5 million. Revenue growth was driven by $3.4 million from the Virsys12 and MissionCare acquisitions completed in Q4 2025, plus $4.3 million from organic portfolio growth. Management increased investment in growth initiatives including AI capabilities and Career Networks expansion. The company authorized a $10 million share repurchase program ending September 12, 2026, demonstrating confidence in valuation. Full-year 2026 guidance was reaffirmed at $323–$330 million revenue and $73–$77 million adjusted EBITDA. The rounding bottom pattern emerges post-earnings after initial premarket weakness resolved into consolidation.

A successful rounding bottom breakout above $27.92 resistance would confirm trend reversal, with the conservative target at $23.88 implying near-term consolidation before potential acceleration. Historical rounding bottom structures typically require sustained volume on the breakout—watch for relative volume above 1.2x to confirm conviction. Invalidation occurs decisively below support at $19.47; a close below that level would signal pattern failure and suggest continued downtrend. With a win probability of 62.14%, the pattern suggests reasonable odds of upside, though not overwhelmingly high conviction. Volume confirmation remains critical; current volume is merely inline rather than exceptional.

Despite beating earnings expectations, the stock fell 5.41% in premarket trading post-announcement, suggesting investor concerns over forward guidance and macro conditions. Management noted no significant gross margin improvement expected, with cloud migration initiatives potentially applying downward pressure. Legacy credentialing and scheduling products declined 16–17% year-over-year with ongoing customer migration and attrition. Management highlighted macro and reimbursement pressures on healthcare customers as a potential headwind to future demand. Analyst price targets range from $21 to $40 with a P/E ratio of 35, indicating valuation disparity and divergent expectations. Beta of 0.29 provides some defensive cushion but limits upside velocity. Monitor next quarterly earnings for margin trends and customer churn acceleration.